Search research articles
Contact Us
Filters
Showing results (1-10 of 33) with videos related to
Page
of 4
Sort By:
Plos One
|
April 22, 2020
Using the Bayesian credible subgroups method to identify populations benefiting from treatment: An application to the Look AHEAD trial
Anna Coonan, Patrick Schnell, Joel Smith, et al.
Digital Health
|
July 15, 2022
Outpatient portal use among pregnant individuals: Cross-sectional, temporal, and cluster analysis of use
Evan Morgan, Patrick Schnell, Priti Singh, et al.
Journal of the Royal Statistical Society. Series C, Applied Statistics
|
June 24, 2017
A marginal cure rate proportional hazards model for spatial survival data
Patrick Schnell, Dipankar Bandyopadhyay, Brian J Reich, et al.
Plos One
|
February 27, 2020
Bayesian credible subgroup identification for treatment effectiveness in time-to-event data
Duy Ngo, Richard Baumgartner, Shahrul Mt-Isa, et al.
Cancer Medicine
|
January 30, 2016
Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007)
Sai-Hong Ignatius Ou, Yiyun Tang, Anna Polli, et al.
The Oncologist
|
June 27, 2025
Long-term safety analysis of pooled data for tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers
Caicun Zhou, Rose Huang, Yuan Yuan, et al.
Research Square
|
July 17, 2025
Dance-based avenues to advance nonpharmacologic treatment of chemotherapy effects (DAANCE): Study protocol for a multi-center, randomized controlled trial
Bhillie Luciani, Martha Carlson, Gretchen McNally, et al.
Trials
|
February 21, 2026
Dance-based avenues to advance nonpharmacologic treatment of chemotherapy effects (DAANCE): study protocol for a multi-center, randomized controlled trial
Bhillie D Luciani, Aya Alwan, Martha Carlson, et al.
Breast (Edinburgh, Scotland)
|
August 13, 2021
Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2
Karen Gelmon, Janice M Walshe, Reshma Mahtani, et al.
Clinical and Translational Science
|
March 22, 2024
Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors
Tian Yu, Xiangyu Liu, Chi-Yuan Wu, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 33) with videos related to
Sort By:
Page
of 4
Plos One
|
April 22, 2020
Using the Bayesian credible subgroups method to identify populations benefiting from treatment: An application to the Look AHEAD trial
Anna Coonan, Patrick Schnell, Joel Smith, et al.
Digital Health
|
July 15, 2022
Outpatient portal use among pregnant individuals: Cross-sectional, temporal, and cluster analysis of use
Evan Morgan, Patrick Schnell, Priti Singh, et al.
Journal of the Royal Statistical Society. Series C, Applied Statistics
|
June 24, 2017
A marginal cure rate proportional hazards model for spatial survival data
Patrick Schnell, Dipankar Bandyopadhyay, Brian J Reich, et al.
Plos One
|
February 27, 2020
Bayesian credible subgroup identification for treatment effectiveness in time-to-event data
Duy Ngo, Richard Baumgartner, Shahrul Mt-Isa, et al.
Cancer Medicine
|
January 30, 2016
Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007)
Sai-Hong Ignatius Ou, Yiyun Tang, Anna Polli, et al.
The Oncologist
|
June 27, 2025
Long-term safety analysis of pooled data for tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers
Caicun Zhou, Rose Huang, Yuan Yuan, et al.
Research Square
|
July 17, 2025
Dance-based avenues to advance nonpharmacologic treatment of chemotherapy effects (DAANCE): Study protocol for a multi-center, randomized controlled trial
Bhillie Luciani, Martha Carlson, Gretchen McNally, et al.
Trials
|
February 21, 2026
Dance-based avenues to advance nonpharmacologic treatment of chemotherapy effects (DAANCE): study protocol for a multi-center, randomized controlled trial
Bhillie D Luciani, Aya Alwan, Martha Carlson, et al.
Breast (Edinburgh, Scotland)
|
August 13, 2021
Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2
Karen Gelmon, Janice M Walshe, Reshma Mahtani, et al.
Clinical and Translational Science
|
March 22, 2024
Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors
Tian Yu, Xiangyu Liu, Chi-Yuan Wu, et al.
Page
of 4